It is widely known that angiogenesis plays a key role in endometriotic lesion formation and development. Antiangiogenic treatments aimed at inhibiting new vessel formation have proven efficient in experimental models. However, as antiangiogenic strategies do not target pre-existing pericyte-protected vessels, they require chronic administration and are likely to be beneficial for early-stage disease only or to prevent recurrence after surgery. Moreover, they may have detrimental effects on reproductive function. Vascular-disrupting agents (VDAs) have emerged as a promising new tool for the treatment of tumors. VDAs target established blood vessels, resulting in tumor ischemia and necrosis. These agents may therefore be more efficient against advanced disease. Two major types of VDAs are being developed for cancer: ligand-directed VDAs using antibodies, peptides and growth factors to deliver toxic effectors to tumor endothelium; and small-molecule VDAs exploiting physiological differences between tumor and normal endothelium to induce acute vascular shut-down. The ongoing evolution in genomics and proteomics is revolutionizing the discovery of novel endothelial markers. Several studies suggest that the vasculature of endometriotic lesions may have particular pathophysiological properties, which could be exploited for the development of selective VDAs. The aim of this review is to explore the merits and limitations of vascular therapy for the treatment of endometriosis.
INTRODUCTION
Endometriosis is a common benign gynecological disorder, which may develop into aggressive disease in some women. It is defined as the presence of endometrial tissue, including both glandular epithelium and stroma, outside the uterine cavity. Endometriosis is associated with various distressing symptoms such as dysmenorrhea, dyspareunia, pelvic pain and subfertility, and often has serious long-term detrimental effects on the professional, social and marital life of sufferers.
Based on its clinical presentation, the disease can be classified into three different types: The main trophic hormone for endometriotic lesions is estrogen (Giudice and Kao, 2004) , and so the majority of endocrine and pharmacological therapies currently in use are based on generating a hypoestrogenic milieu. Unfortunately, the disease often recurs after cessation of treatment, underlining the importance of developing new treatment strategies.
Surgical treatment, either conservative or radical, is becoming the treatment of choice.
In case of moderate and severe endometriosis-associated infertility, the combined approach (operative laparoscopy and postoperative medical treatment) may be recommended (Donnez et al., 2002b ). Cumulative recurrence rates after conservative surgery can be as high as 50-70% (Fedele et al., 1994) . It is evident that any treatment option which reduces the need for these invasive procedures would be a welcome alternative.
Thanks to recent advances in the understanding of the mechanisms underlying the development of this multifactorial disease, new therapeutic strategies have been proposed and are currently being tested in experimental models (Ferrero et Physiological angiogenesis is essential for embryogenesis, but rarely occurs in adults, except in reproductive tissues and wound healing. In women, profound nonpathological angiogenesis is seen in the ovary during corpus luteum formation and in the endometrium during the menstrual cycle (Smith, 1998) . This is unusual since the vasculature is normally in a state of quiescence maintained by a balance between inhibitors and activators of angiogenesis.
Disruption of this balance in favor of excessive angiogenesis results in conditions such as rheumatoid arthritis, diabetic retinopathy, psoriasis and cancer. At least four different mechanisms of angiogenesis have been identified: sprouting, intussusception (internal division of vessels resulting in vessel splitting), elongation or incorporation of circulating or progenitor endothelial cells into vessels (Risau, 1997; Girling and Rogers, 2005) . It is a complex and precisely regulated process involving a number of coordinated sequences of cellular interactions. The maturation of newly formed angiogenic blood vessels implies the recruitment of pericytes and smooth muscle cells, which are essential to stabilize vessels. In sprouting angiogenesis, angiogenic stimuli induce vascular endothelial cell activation, breakdown of the basement membrane, migration and proliferation of endothelial cells and tube formation (Folkman and Singh, 1992) .
ANGIOGENIC AND MATURE VESSELS IN ENDOMETRIOTIC LESIONS
It is generally recognized that the establishment of an effective blood supply is essential Available data on the vascularization of rectovaginal or deep invasive endometriosis are also limited. Deep-infiltrating endometriosis in the sigmoid and rectovaginal septum is well vascularized , and vascularization is increased in deep invasive endometriosis affecting the rectum (Machado et al., 2008) . However, most blood vessels appear to be nonangiogenic because they are covered with αSMA-positive smooth muscle cells (Conway et al., 2001 ). These findings clearly show that angiogenesis is frequently associated with the disease and its immediate environment.
EARLY ENDOMETRIOSIS DEVELOPMENT DEPENDS ON ANGIOGENESIS
In order to study the initial steps of endometriotic lesion formation, various animal, ex vivo and in vitro experimental models have been developed (Laschke and Menger, 2007) .
Analysis of endometriotic lesion revascularization in these models shows that an adequate angiogenic response is required for the successful survival and growth of ectopic There are numerous indications that the human endometrium itself is highly angiogenic, and it has been hypothesized that pathological changes in angiogenesis in eutopic endometrium can contribute to the initiation of endometriosis (Laschke and Menger, 2007) .
Endothelial cell proliferation is increased in endometrium from patients with endometriosis (Wingfield et al., 1995) and microvessel density is higher (Bourlev et al., 2006) . Several proangiogenic factors are overexpressed or disregulated in endometrium from these patients 
VASCULAR-DISRUPTING AGENTS: DEFINITION AND POTENTIAL BENEFITS FOR ENDOMETRIOSIS TREATMENT
A new type of vascular-targeted therapy has recently emerged for cancer treatment:
vascular-disrupting agents (VDAs) designed to act upon the established vasculature. They differ from antiangiogenic approaches in three key respects: their physiological target, the type or extent of disease likely to be susceptible, and the treatment modalities (Table 3) .
Unlike antiangiogenic drugs effective for preventing neovascularization, VDAs target established blood vessels (Siemann et al., 2005) . These agents are therefore given acutely and may be particularly effective against advanced disease (Lippert, 2007) . Two major types of 
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Small molecule vascular-disrupting agents
VDAs exploit pathophysiological differences between endothelium in normal and diseased tissue to achieve selective occlusion of blood vessels. Disease-related characteristics that can be taken advantage of include increased proliferation, permeability, and reliance on cytoskeletal proteins to maintain cell shape (Thorpe, 2004) . 
Ligand-based targeting
An alternative way of delivering drugs to diseased tissues is by means of selective binding to molecules specific to the endothelium of the tissue. Ligand-directed VDAs contain molecules that specifically bind to antigens on or in endothelial cells to achieve selectivity, Triggering the immune system to attack blood vessels in endometriotic lesions by means of vaccination therefore shows promise. However, safeguarding the selectivity of the response poses a major challenge.
Ligand-based disease-specific molecule targeting
Potential targets for ligand-based vascular disruption in cancer include VEGF receptor (VEGFR), αvβ3 integrin, fibronectin and annexin A1 (Brack et al., 2004) . Most of these markers, typically associated with endothelial cell activation, were also reported to be overexpressed in endothelial cells of eutopic endometrium or endometriotic lesions (Table 1) . 
Screening approaches to identify potential endothelial markers
Various high-throughput screening approaches have been applied to discover novel endothelial cell surface markers in disease models or human tissue biopsies, as summarized in Table 4 .
In animal models, screening of tissue-specific endothelial cell surface markers can be achieved by in vivo labeling of vascular structure, followed by recovery of endothelial cells and comparative proteomic or genomic screening approaches (Brack et Identification of tissue-specific and disease-specific endothelial cell markers has opened up new perspectives for the development of novel drugs designed to selectively disrupt tumor vessels. Since inflammatory angiogenesis in endometriosis has many features in common with tumor angiogenesis, it is likely that these findings could be extrapolated to this disease.
However, the specifics of each individual chronic inflammatory situation should be taken into account.
The molecular signature on the endothelial cell surface of any organ or diseased tissue is distinct from that found in other tissues, and can be probed for specific cell surface antigens.
Alternatively, the vasculature of lesions may have different pathophysiological properties from normal vessels, which can be exploited for the development of selective drugs.
Unfortunately 
